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Transforming growth factor β-activated kinase 1 (TAK1) is critical for survival of many KRAS mutated
colorectal cancer cells, and TAK1 inhibition with 5Z-7-oxozeaenol has been associated with oxidative
stress leading to tumor cell killing. When SW 620 and HCT 116 human colon cancer cells were treated
with 5 mM 5Z-7-oxozeaenol, cell viability, growth, and clonogenic survival were signiﬁcantly decreased.
Consistent with TAK1 inhibition being causally related to thiol-mediated oxidative stress, 10 mM
N-acetylcysteine (NAC) partially reversed the growth inhibitory effects of 5Z-7-oxozeaenol. In addition,
5Z-7-oxozeaenol also increased steady-state levels of H2DCFDA oxidation as well as increased levels of
total glutathione (GSH) and glutathione disulﬁde (GSSG). Interestingly, depletion of GSH using buthio-
nine sulfoximine did not signiﬁcantly potentiate 5Z-7-oxozeaenol toxicity in either cell line. In contrast,
pre-treatment of cells with auranoﬁn (Au) to inhibit thioredoxin reductase activity signiﬁcantly increased
levels of oxidized thioredoxin as well as sensitized cells to 5Z-7-oxozeaenol-induced growth inhibition
and clonogenic cell killing. These results were conﬁrmed in SW 620 murine xenografts, where treatment
with 5Z-7-oxozeaenol or with Au plus 5Z-7-oxozeaenol signiﬁcantly inhibited growth, with Au plus 5Z-
7-oxozeaenol trending toward greater growth inhibition compared to 5Z-7-oxozeaenol alone. These
results support the hypothesis that thiol-mediated oxidative stress is causally related to TAK1-induced
colon cancer cell killing. In addition, these results support the hypothesis that thioredoxin metabolism is
a critical target for enhancing colon cancer cell killing via TAK1 inhibition and could represent an ef-
fective therapeutic strategy in patients with these highly resistant tumors.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Up to 60% of patients with colorectal cancer will develop me-
tastatic disease [1]. The treatment of metastatic colon cancer de-
pends, in part, on KRAS mutation status. Colon cancers that are
wild-type KRAS can be treated with monoclonal antibodies such as
cetuximab and panitumumab against the epidermal growth factor
receptor (EGFR), and a proportion of individuals will have en-
hanced survival because of these treatments [2–4]. Unfortunately,
tumors harboring KRAS mutations are unresponsive to these anti-
EGFR therapies. Furthermore, even those tumors which are in-
itially KRAS wild-type often develop resistance to EGFR blockadeB.V. This is an open access article u
ion of Surgical Oncology and
a City, IA 52242, USA.
zhir).[5,6]. In these cases, patients have limited treatment options.
Transforming growth factor β-activated kinase 1 (TAK1) has
recently been identiﬁed as a pro-survival signaling pathway for
KRAS mutant colon cancer cell lines. Inhibition of TAK1 has been
shown to impair growth and is suggested to increase steady-state
levels of reactive oxygen species (ROS) in KRAS mutant cells;
however the causal role of oxidative stress in the cell killing in-
duced by 5Z-7-oxozeaenol has not been established [7–9]. 5Z-7-
oxozeaenol is a commercially available irreversible inhibitor of
TAK1 and ATPase activity. Within 20 min of treatment, over 90% of
TAK1 is irreversibly bound by 5Z-7-oxozeaenol [8]. Since KRAS
activation is thought to increase steady-state levels of pro-oxi-
dants in cancer cells [9], and modest increases in ROS are thought
to enhance pro-survival pathways such as TAK1 making cells re-
sistant to oxidative stress [10], we reasoned that TAK1 inhibition in
KRAS mutant colon cancer cells would render them unable to
adapt to endogenous metabolic oxidative stress associated withnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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dant levels and enhanced oxidative stress-induced cell killing.
In the current study, we tested the hypothesis that inhibition of
TAK1 with 5Z-7-oxozeaenol would enhance steady-state levels of
H2DCFDA oxidation and induce cell killing by a mechanism in-
volving oxidative stress in KRAS mutant colon cancer cell lines. We
found that 5Z-7-oxozeaenol led to increased levels of H2DCFDA
oxidation, increased levels of total and oxidized glutathione, and
clonogenic cell killing. Furthermore, both increases in H2DCFDA
oxidation and clonogenic cell killing mediated by 5Z-7-oxozeaenol
were inhibited by the thiol antioxidant, N-acetylcysteine (NAC).
Interestingly, depletion of glutathione with buthionine sulfox-
imine did not signiﬁcantly enhance cell killing by TAK1 inhibition.
In contrast, inhibition of thioredoxin reductase with auranoﬁn
signiﬁcantly enhanced cell killing mediated by 5Z-7-oxozeaenol.
These results support the hypothesis that TAK1-induced KRAS
mutant colon cancer cell killing is causally related to thiol-medi-
ated oxidation. This work also suggests that thioredoxin metabo-
lism is a critical target for enhancing colon cancer cell killing with
TAK1 inhibition and may represent an effective treatment strategy
for these highly resistant cancers.Materials and methods
Cell lines, media, and culture conditions
HCT 116, a colorectal adenocarcinoma cell line isolated from a primary tumor,
and SW 620, a colorectal carcinoma cell line isolated from a lymph node metastasis,
were obtained from ATCC (Manassas, VA; products CCL-247 and CCL-227, respec-
tively). Both are KRAS mutant. HCT 116 cells were maintained in Dulbecco's
Modiﬁed Eagle Medium (Gibco/Life Technologies, Grand Island, NY) and SW 620
were maintained in Leibovitz's L-15 Medium (Gibco/Life Technologies, Grand Is-
land, NY), both supplemented with 10% FBS and 100 U/mL penicillin/streptomycin.
Both cell lines were maintained at 37 °C and 5% CO2. Routine subculture was per-
formed by washing with 1 PBS and detaching cells with TrypLE Express (Life
Technologies, Grand Island, NY).
Drug treatment
Cells were treated with 5Z-7-oxozeaenol (TAK1 inhibitor) (Cat. no. O9890,
Sigma-Aldrich, St. Louis, MO). A stock solution of Z-7-oxozeaenol inhibitor in DMSO
was added to achieve a ﬁnal concentration of 5 mM in media. DMSO (0.1%) was used
as the vehicle control in all cases. Injectable N-acetylcysteine (NAC) (Acetadote,
Cumberland Pharmaceuticals, Nashville, TN) was added 1 h following treatment
with TAK1 inhibitor to achieve a ﬁnal concentration of 10 mM. Buthionine sul-
foximine (BSO) dissolved in PBS (Sigma-Aldrich, St. Louis, MO) was added 8 h prior
to the addition of TAK1 inhibitor to a ﬁnal concentration of 100 mM. Cells were
treated with auranoﬁn dissolved in absolute ethanol (Enzo Life Sciences, Farm-
ingdale, NY) 3 h prior to treatment with TAK1 inhibitor to achieve a ﬁnal con-
centration of 500 nM (0.1% ethanol). Treatments were added directly to the com-
plete media speciﬁc for each cell line.
Cell viability assay
The effect of TAK1 inhibition on cell viability and the ability of NAC to coun-
teract that effect was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay. Cells were seeded at a density of 5104 in a
96-well plate and incubated at 37 °C. After 24 h, cells were treated with TAK1 in-
hibitor, with and without subsequent NAC treatment. After 24 h of incubation,
100 mL of 0.5 mg/mL MTT (Sigma-Aldrich, St. Louis, MO) was added to each well for
4 h, following which the media with MTT was removed, cells were washed with
PBS, and 100 mL DMSO was added to each well as the solubilizing agent. A mi-
croplate reader was used to read absorbance at 540 nm, and cell viability was
determined by dividing the average absorbance of treated cells by untreated cells.
Growth curves
The effect of TAK1 inhibition, glutathione depletion, and thioredoxin reductase
inhibition on cell growth was determined as follows. Cells were plated at time 0.
Time points for treatment varied by drug and were as follows: at time 16 h, BSO
was added; at 21 h, auranoﬁn; at 24 h, TAK1 inhibitor; at 25 h, NAC. Cell counts
were obtained 48, 72, and 96 h following plating. Cells were detached with TrypLEExpress and then viable cells were counted using the Countess Automated Cell
Counter (Life Technologies, Grand Island, NY).
Clonogenic survival assay
The ability of individual clones to proliferate following treatment with TAK1
inhibitor, BSO, or auranoﬁn was measured by clonogenic cell survival assay. Brieﬂy,
cells were plated in 6-well dishes, treatment was applied as speciﬁed in each ex-
periment: at time 16 h, BSO; at 21 h, auranoﬁn; at 24 h, TAK1 inhibitor; at 25 h,
NAC. At 48 h, cells were rinsed with PBS, detached with TrypLE Express, counted,
and then plated in media without drug treatment at low density (100–500 cells per
dish). Clones were allowed to grow for 14 days, at which point they were ﬁxed with
70% ethanol and stained with 0.5% w/v crystal violet in methanol. Colonies of
greater than 50 cells were counted. Cloning efﬁciency was calculated as the number
of colonies per plate divided by the number of cells plated and data from drug
treated dishes was normalized to the respective sham treated control.
Flow cytometry
Alterations in non-speciﬁc intracellular oxidation reactions caused TAK1 in-
hibition, and the ability of NAC to suppress these changes, was measured by fol-
lowing the oxidation of the ﬂuorescent probe 6-carboxy-2′,7′-dichlorodihydro-
ﬂuorescein diacetate (Carboxy-H2DCFDA, C-400, Molecular Probes/Life Technolo-
gies, Grand Island, NY). Following 24 h of treatment with TAK1 inhibitor, with and
without subsequent NAC treatment, cells were washed with PBS twice and then
incubated for 15 min at 37 °C with 10 mg/mL Carboxy-H2DCFDA. Carboxy-H2DCFDA
is nonﬂuorescent and membrane permeable; its ester groups undergo cleavage by
intracellular esterases, followed by non-speciﬁc pro-oxidant mediated oxidation of
the oxidation sensitive bond to yield the ﬂuorescent product dichloroﬂuorescein
(DCF). The oxidation insensitive probe Carboxy-DCFDA (C-369, Molecular Probes/
Life Technologies, Grand Island, NY) was used as a control in each experiment to
ensure that increased DCF ﬂuorescence was due to changes in dye oxidation, rather
than to changes in dye uptake, efﬂux, or ester cleavage. Fluorescence was detected
with a Beckton Dickinson LSR II ﬂow cytometer using 488 nm excitation and
525 nm emission. Results of the Mean Florescence Intensity (MFI) of 10,000 cells
obtained with the oxidation sensitive probe were normalized to the MFI of the
respective treatment group labeled with the oxidation insensitive probe, to show
that changes in dye oxidation (and not dye uptake, ester cleavage, or efﬂux) were
being detected.
Glutathione assay
Cells were plated at a density of 2106 in 150 mm dishes. At 16 h, BSO was
applied; at 24 h, TAK1 inhibitor; and at 25 h, NAC. At 48 h, cells were washed in
cold PBS and then scraped into 200 mL of 5% 5-sulfosalicylic acid (Sigma-Aldrich, St.
Louis, MO) in water. Total GSH content was measured as described previously [11].
Glutathione disulﬁde (GSSG), the oxidized form of GSH, was measured by adding
20 mL of a 1:1 mixture of 2-vinylpyridine and ethanol per 100 mL of sample, in-
cubating for 2 h, and assaying as previously described [12]. Glutathione determi-
nations were normalized to the protein content using the BCA protein assay
(Thermo Fisher Scientiﬁc, Waltham, MA). Overall values were normalized to vehicle
control.
Thioredoxin reductase activity
Thioredoxin reductase (TrxR) activity was determined in cell homogenates
spectrophotometrically using previously described methods (CSO170 Sigma-Al-
drich, St. Louis, MO) [13]. Enzymatic activity was assessed by determining the
difference between the time-dependent increase in absorbance at 412 nm in the
presence of the TrxR activity inhibitor from total activity. One activity unit equaled
1 mmol/L 5′-thionitrobenzoic acid formed/(min mg protein). Lowry assay was used
to determine protein concentrations.
Thioredoxin Western
Oxidized and reduced forms of thioredoxin (Trx) were separated based on the
method described previously [13,14]. Cells were plated in 100 mm dishes and
treated with auranoﬁn at 21 h, with TAK1 inhibitor at 24 h, and with NAC at 25 h.
At 48 h, cells were harvested by scraping into G-lysis buffer containing 50 mM
iodoacetic acid, incubating at 37° for 30 min, then removing excess iodoacetic acid
with desalting spin columns (illustra MicroSpin G-25 columns, GE Healthcare,
Pittsburgh, PA). Equal amounts of total protein prepared in a non-denaturing, non-
reducing buffer were loaded into a 15% non-denaturing, non-reducing gel that was
then electroblotted to nitrocellulose membrane. Blots were probed for Trx using
anti-Trx-1 primary antibody (Cell Signaling, Boston, MA). Goat anti-rabbit HRP-
conjugated IgG (BD Transduction Laboratories, San Diego, CA) was used for the
secondary antibody. Chemiluminescent detection was performed with Super Signal
J.E. Hrabe et al. / Redox Biology 5 (2015) 319–327 321West Pico Chemiluminescent Reagent (Pierce, Rockford, IL) on a Typhoon FLA 7000
ﬂuorescent detection system. Band densities were calculated with ImageJ software
as previously described [15].0
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Athymic, female nu/nu nude mice 6–8 weeks old were purchased from Harlan
Laboratories (Indianapolis, Indiana) and housed in the Animal Care Facility at the
University of Iowa. All procedures conformed to National Institutions of Health
established guidelines and were approved by the Institutional Animal Care and Use0
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J.E. Hrabe et al. / Redox Biology 5 (2015) 319–327322Committee of the University of Iowa. 2106 SW 620 cells were injected sub-
cutaneously into mice hind limbs. Following 11 days of tumor growth, mice were
randomly assigned to one of four treatment groups: vehicle control (sterile 2.5%
DMSO in vegetable oil); 5Z-7-oxozeaenol (ENZO Life Science ALX-380-267-M005)
15 mg/kg, dissolved in sterile DMSO (ﬁnal concentration 2.5%) and vegetable oil;
auranoﬁn 1.6 mg/kg, dissolved in sterile DMSO and vegetable oil; and a combina-
tion of 5Z-7-oxozeaenol and auranoﬁn. The drugs were administered via in-
traperitoneal injection for ﬁve consecutive days, followed by 2 days of auranoﬁn
only, and then four more consecutive days of combination treatment. Tumor0.0
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(GSH), (B) and oxidized glutathione (GSSG), (C) levels were assayed. Normalized to vehi
**P o0.05.volume was measured daily by calipers by an individual blinded to the treatment
group, and tumor volumes calculated.
Statistical analysis
For in vitro work, statistical analysis was done using GraphPad Prism version
6.0 for (GraphPad Software, La Jolla, CA). To determine differences between 3 or
more means, one-way ANOVA with least signiﬁcant difference posttests were
performed. Error bars represent the standard error of the mean. All statistical0.0
0.5
1.0
1.5
+
-
-
-
+
-
-
+
+
* *
SW 620
0
50
100
150
SW 620
+
-
-
+
**
0
50
100
150
200
SW 620
+
-
-
+
**
ibition with increased intracellular glutathione. Cells were treated with 5 mM 5Z-7-
was used to analyze intracellular reactive oxygen species generation after 24 h of
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J.E. Hrabe et al. / Redox Biology 5 (2015) 319–327 323analysis was performed at the P o0.05 level of signiﬁcance.
For tumor volume in the murine model, linear mixed effects regression models
were used to estimate and compare group-speciﬁc tumor growth curves. Pairwise
comparisons were performed to identify speciﬁc group differences in the growth
curves. All tests were two-sided and carried out at the 5% level of signiﬁcance.
Analyses were performed with SAS version 9.3 (SAS Institute Inc., Cary, NC).Fig. 3. Depleting intracellular glutathione had little effect on cell growth and clonogenic s
for 8 h to deplete intracellular glutathione, then treated with 5 mM 5Z-7-oxozeaenol. (A
tathione levels, shown as normalized to vehicle control, were assayed. (B) Cells were plat
96 h after plating to determine cell growth rate. (C) After 24 h of treatment, cells were de
ﬁxed, stained, and counted to determine the rate of clonogenic survival. Values represen
*P-valueo0.01. **P-valueo0.05.Results
Cell viability, growth, and clonogenic survival are impaired by TAK1 inhibition but
restored with NAC, suggesting a role for oxidative stress in TAK1-mediated tumor cell
death
Treatment with the TAK1 inhibitor 5Z-7-oxozeaenol has been shown to in-
crease apoptosis in several KRAS-mutated colorectal cancer cells [7], though the
mechanism is not entirely understood. To investigate this, we characterized theurvival when coupled with TAK1 inhibition. Cells were pretreated with 100 mM BSO
) After 24 h of treatment, cells were scrape harvested and total intracellular glu-
ed at time 0 and treatment applied at 24 h; cell counts were obtained at 48, 72, and
tached using TrypLE Express and plated at low density. 14 days later, colonies were
t mean71 SEM of at least 3 separate experiments. #P-valueo0.01 versus control.
J.E. Hrabe et al. / Redox Biology 5 (2015) 319–327324effects of TAK1 inhibition on viability, cell growth, and the ability of human colon
cancer cells to form clonal populations. Following 24 h of treatment with the TAK1
inhibitor, cell viability was measured using the MTT assay. HCT 116 and SW 620
cells treated with TAK1 inhibitor had signiﬁcantly decreased viability compared to
vehicle control cells, which was restored by treating with NAC 1 h after addition of
5Z-7-oxozeaenol (Fig. 1A).
Similar effects on cell growth and clonogenic survival were seen following
treatment with TAK1 inhibitor and again these growth inhibitory effects were re-
versed by NAC (Fig. 1B and C). The addition of NAC restored clonogenic survival in
both cell lines, however, the results did not reach statistical signiﬁcance in HCT 116;
SW 620 clonogenic survival was completely restored to that of controls. NAC's
ability to abrogate the toxic effects of TAK1 inhibition suggests that thiol-mediated
oxidative stress may be important to the mechanism by which cell viability,
growth, and clonogenic survival are impaired.
TAK1 inhibition leads to an increase in steady-state levels of pro-oxidants and an
upregulation of glutathione metabolism
Relative to the oxidation insensitive analog of the dye, H2DCFDA oxidation was
signiﬁcantly increased in both HCT 116 and SW 620 cells treated with 5Z-7-ox-
ozeaenol. This effect was abrogated by treatment with NAC (Fig. 2A). These results
show that TAK1 inhibition is accompanied by an increase in non-speciﬁc in-
tracellular pro-oxidants that can be inhibited by NAC. Furthermore, these results
are consistent with the hypothesis that there is a causal relationship between
TAK1-induced cell killing and thiol-mediated oxidative stress.Vehicle
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(trx). (C) Semiquantitative analysis of Western blots for oxidized to total thioredoxin. V
versus control. **P-valueo0.05.As glutathione is the major soluble thiol antioxidant, we examined whether
this increase in pro-oxidants was accompanied by changes in intracellular glu-
tathione (GSH) levels. We examined both the total cellular GSH as well as the
amount of glutathione disulﬁde (GSSG). In both HCT 116 and SW 620 cell lines, total
GSH as well as GSSG were signiﬁcantly increased when cells were exposed to TAK1
inhibitor (Fig. 2B and C). The increase in total GSH and GSSG suggests greater
amounts of both synthesis and oxidation of glutathione, which is in accordance
with the increased H2DCFDA oxidation demonstrated by ﬂow cytometry causing
oxidative stress.
Depleting glutathione did not potentiate the effects of TAK1 inhibition
Given the protective effects of the thiol antioxidant NAC as well as the increase
in glutathione when cells were treated with 5Z-7-oxozeaenol, we hypothesized
that glutathione depletion would render cells more vulnerable to the effects of the
TAK1 inhibitor. Cells were pre-treated with BSO, an irreversible inhibitor of γ-
glutamylcysteine synthetase, the rate-limiting enzyme for glutathione synthesis.
We ﬁrst conﬁrmed that intracellular glutathione was signiﬁcantly decreased in
both HCT 116 and SW 620 cells treated with BSO (Fig. 3A). Next, we assayed cell
growth rate and clonogenic survival in cells pretreated with BSO. Surprisingly, BSO
treatment caused no signiﬁcant differences in growth rate (Fig. 3B) or clonogenic
survival (Fig. 3C) between cells treated with 5Z-7-oxozeaenol and those pretreated
with BSO followed by 5Z-7-oxozeaenol. For both cell lines, treatment with BSO
alone did not signiﬁcantly impair either growth or clonogenic survival. From these
data, we concluded that alterations in glutathione metabolism were not central to##
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cancer cells.
Auranoﬁn inhibits thioredoxin reductase (TrxR) and, when combined with 5Z-7-ox-
ozeaenol, leads to an increase in the ratio of oxidized to total thioredoxin
To study the other major intracellular thiol-dependent pathway that may be
responsible for protection from 5Z-7-oxozeaenol, cells were treated with auranoﬁn
to inhibit TrxR. TrxR is critical for regenerating the reduced form of Trx necessary
for reducing protein thiols and driving the catalytic decomposition of hydroper-
oxides by peroxiredoxins [16,17]. TrxR also initiates signaling pathways that affect
gene regulation related to protecting cells from oxidative stress [17]. As such, its
role in cell defense against oxidative stress has been suggested to represent a
signiﬁcant therapeutic target during cancer therapy [18].
We conﬁrmed that auranoﬁn signiﬁcantly inhibited TrxR activity in both HCT
116 and SW 620 cells (Fig. 4A). We then evaluated the effects of auranoﬁn treat-
ment on the redox state of Trx-1. SW 620 cells were treated as previously described
and then analyzed for oxidized and reduced Trx by Western blot (Fig. 4B). Com-
bination treatment with auranoﬁn and 5Z-7-oxozeaenol led to a signiﬁcant in-
crease in the ratio of oxidized to total Trx-1 as compared to either 5Z-7-oxozeaenol
or auranoﬁn alone (Fig. 4B and C).
Inhibition of thioredoxin metabolism potentiates the effects of TAK1 inhibition
When coupled with 5Z-7-oxozeaenol, auranoﬁn led to signiﬁcantly impaired
growth (Fig. 5A) and dramatically reduced clonogenic survival (Fig. 5B) as com-
pared to the TAK1 inhibitor alone in both HCT 116 and SW 620 cells. In contrast to
BSO, auranoﬁn alone had a toxic effect on both cell lines, yielding a statistically
signiﬁcantly slower rate of growth and clonogenic survival as compared to control
(Fig. 5A and B). These results support the hypothesis that HCT 116 and SW 620 cells
are sensitive to the disruption of Trx metabolism, and inhibition of TrxR activity#
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SW 620 xenografts were grown for 11 days in athymic nude mice and were
treated with (1) vehicle control (sterile DMSO in vegetable oil), (2) 5Z-7-oxozeaenol
(15 mg/kg, dissolved in sterile DMSO and vegetable oil), (3) auranoﬁn (1.6 mg/kg,
dissolved in sterile DMSO and vegetable oil), or (4) the combination of 5Z-7-ox-
ozeaenol and auranoﬁn (Fig. 6). The drugs were administered as noted via in-
traperitoneal injection for ﬁve consecutive days. This was followed by 2 days of
treatment with auranoﬁn only, and then four additional consecutive days of ad-
ministration of both drugs. Mice in both the TAK1 inhibitor and the combination
groups lost a signiﬁcant amount of weight during treatment; however they quickly
regained weight both during the 2 days that TAK1 was not given and at the
completion of therapy (data not shown). Auranoﬁn alone did not signiﬁcantly slow
tumor growth as compared to the control group. Mice treated with TAK1 inhibitor
or with TAK1 inhibitor plus auranoﬁn demonstrated signiﬁcantly slowed tumor
growth compared to control. The mice treated with the combination of TAK1 in-
hibitor plus auranoﬁn showed the slowest tumor growth, however this did not
reach statistical signiﬁcance as compared to TAK1 inhibitor alone (P¼0.07).Discussion
Approximately 30–50% of colon cancers harbor KRAS muta-
tions, which are predictive of poor treatment responses to drugs
targeting EGFR thereby limiting therapeutic options for these pa-
tients [4,19,20]. Recent research has stimulated an interest in TAK1
as a potential new therapeutic target for KRAS mutated tumors [7].
In the current study, cancer cell growth inhibitory properties of
TAK1 inhibition were determined in KRAS mutant colon cancer
cells. The results demonstrate that treatment with the TAK1 in-
hibitor 5Z-7-oxozeaenol decreases cancer cell viability, cell growth
rate, and clonogenic cell survival. These effects were all reversed
by adding a non-speciﬁc thiol antioxidant, NAC, which for the ﬁrst
time supported a causal relationship between thiol-mediated
oxidative stress and the growth inhibitory and cytotoxic effects of
TAK1 inhibition on KRAS mutant colon cancer cells.
Other investigators have suggested that TAK1 regulates ROS
levels in endothelial cells [21,22]. We have conﬁrmed the fact that
H2DCFDA oxidation is increased with TAK1 inhibition in KRAS
mutant colon cancer cell lines as well as extending this to show
NAC mitigate the effects of TAK1 inhibition on non-speciﬁc
H2DCFDA oxidation. These novel results continue to support a
causal relationship between TAK1 inhibition-induced thiol-medi-
ated oxidative stress and cancer cell growth inhibition.
We have now also extended the TAK1 inhibition studies in
colon cancer cells to include an analysis of redox state as de-
termine by alterations intracellular GSH/GSSG. GSH is one of the
major thiol redox buffers in cells responsible for ROS detoxiﬁcation
and is associated with cancer cell resistance to chemotherapy [23].
While GSH and GSSG levels were found to be signiﬁcantly in-
creased following treatment with 5Z-7-oxozeaenol, consistent
with TAK1 inhibition inducing oxidative stress; GSH depletion
using BSO did not sensitize the colon cancer cell lines to 5Z-7-
oxozeaenol suggesting that GSH-independent thiol metabolic
pathways were important in colon cancer cell resistance to TAK1
inhibition.
We next interrogated thioredoxin-dependent metabolism
using the TrxR inhibitor, auranoﬁn [24]. In contrast to the results
seen with GSH depletion, growth inhibition and clonogenic cell
killing following exposure to 5Z-7-oxozeaenol was signiﬁcantly
enhanced in colon cancer cells treated with auranoﬁn as was
oxidation of Trx. Auranoﬁn is well-tolerated in humans at blood
levels in the high nM to low mM range and is currently used for the
treatment of rheumatoid arthritis [18,25,26]. Therefore the current
results showing auranoﬁn-mediated inhibition of TrxR activity
sensitizing colon cancer cells to TAK1 inhibition suggest a rapidly
translatable biochemical strategy for improving the efﬁcacy of 5Z-
7-oxozeaenol in vivo.In order to test the efﬁcacy of TAK1 inhibitors in vivo, SW 620
cells were grown as xenografts in nude mice and treated with the
combination of auranoﬁn and 5Z-7-oxozeaenol. Fig. 6 shows that
treatment with 5Z-7-oxozeaenol or treatment with auranoﬁn plus
5Z-7-oxozeaenol signiﬁcantly inhibited xenograft growth although
the effect of auranoﬁn was not as dramatic in vivo as in vitro. This
could be the result of drug availability in the solid tumors gov-
erned by tissue perfusion or other complexities of the tumor mi-
croenvironment such as O2 concentration. However, these results
do continue to support the hypothesis derived from the in vitro
data that thiol-mediated oxidative stress is causally related to
TAK1-induced KRAS mutant colon cancer cell killing.
TAK1 has been shown to be critical for survival in KRAS-mu-
tated colon cancer cells [7]. KRAS mutations are associated with
higher steady-state levels of pro-oxidants derived from signaling
pathways that have been demonstrated to be critical to inducing
pro-survival pathways in cancer cells [27]. However, there is a
delicate balance between pro-oxidant levels and KRAS activation
of cellular metabolic pathways for scavenging pro-oxidants (such
as O2 and H2O2) that is necessary to inhibit metabolic oxidative
stress, allowing for pro-oxidant-mediated growth stimulation.
Because of this delicate balance, it is perhaps not surprising that
drug treatments that result in an over-abundance of ROS are able
to selectively kill KRAS mutated cells [9]. Consistent with the no-
tion that KRAS mutant cells need to activate TAK1 for protection
against metabolic oxidative stress, it has been shown by us and
others that TAK1 inhibition can increase steady-state levels of pro-
oxidants in colon cancer cells lines and in murine small intestine
epithelium [22,28,29]. Finally, our results support the speculation
that TAK1 inhibition combined with inhibition of thioredoxin
metabolism may represent a signiﬁcant target for potentiating the
effects of chemotherapeutic agents in KRAS mutant colon cancers
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